![]() | ![]() |
Formats:
|
||||||||||||||||||||||||||||
Copyright © 2008 Martínez et al; licensee BioMed Central Ltd. Coutilization of glucose and glycerol enhances the production of aromatic compounds in an Escherichia coli strain lacking the phosphoenolpyruvate: carbohydrate phosphotransferase system 1Departamento de Ingeniería Celular y Biocatálisis, Instituto de Biotecnología, Universidad Nacional Autónoma de México (UNAM), Av. Universidad 2001 CP 62210, Cuernavaca, Morelos, México 2Departamento de Medicina Molecular y Bioprocesos, Instituto de Biotecnología, Universidad Nacional Autónoma de México (UNAM), Av. Universidad 2001 CP 62210, Cuernavaca, Morelos, México Corresponding author.Karla Martínez: karlamg/at/ibt.unam.mx; Ramón de Anda: deanda/at/ibt.unam.mx; Georgina Hernández: ginah/at/ibt.unam.mx; Adelfo Escalante: adelfo/at/ibt.unam.mx; Guillermo Gosset: gosset/at/ibt.unam.mx; Octavio T Ramírez: tonatiuh/at/ibt.unam.mx; Francisco G Bolívar: bolivar/at/ibt.unam.mx Received October 2, 2007; Accepted January 22, 2008. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. This article has been cited by other articles in PMC.Abstract Background Escherichia coli strains lacking the phosphoenolpyruvate: carbohydrate phosphotransferase system (PTS) are capable of coutilizing glucose and other carbon sources due to the absence of catabolite repression by glucose. In these strains, the lack of this important regulatory and transport system allows the coexistence of glycolytic and gluconeogenic pathways. Strains lacking PTS have been constructed with the goal of canalizing part of the phosphoenolpyruvate (PEP) not consumed in glucose transport to the aromatic pathway. The deletion of the ptsHIcrr operon inactivates PTS causing poor growth on this sugar; nonetheless, fast growing mutants on glucose have been isolated (PB12 strain). However, there are no reported studies concerning the growth potential of a PTS- strain in mixtures of different carbon sources to enhance the production of aromatics compounds. Results PB12 strain is capable of coutilizing mixtures of glucose-arabinose, glucose-gluconate and glucose-glycerol. This capacity increases its specific growth rate (μ) given that this strain metabolizes more moles of carbon source per unit time. The presence of plasmids pRW300aroGfbr and pCLtktA reduces the μ of strain PB12 in all mixtures of carbon sources, but enhances the productivity and yield of aromatic compounds, especially in the glucose-glycerol mixture, as compared to glucose or glycerol cultures. No acetate was detected in the glycerol and the glucose-glycerol batch fermentations. Conclusion Due to the lack of catabolite repression, PB12 strain carrying multicopy plasmids containing tktA and aroGfbr genes is capable of coutilizing glucose and other carbon sources; this capacity, reduces its μ but increases the production of aromatic compounds. Background Glucose is the preferred carbon source for Escherichia coli (E. coli); the presence of this monosaccharide inhibits the utilization of secondary carbon sources. This process is known as carbon catabolite repression, and the phosphoenolpyruvate: carbohydrate phosphotransferase system (PTS) is the main regulator of this response. The PTS components EI, HPr, EIIAGlc, EIICBGlc encoded by the ptsHIcrr operon and the ptsG gene, as well as other important proteins like the adenylate cyclase (Cya) and the cAMP-CRP complex, are members of the carbon catabolite modulon regulating the activities of genes involved in carbon transport [1-5]. The inactivation of PTS has pleiotropic effects in E. coli. It has been demonstrated that the deletion of the ptsHIcrr operon drastically reduces the specific growth rate (μ) of the cell (from 0.7 to 0.1 hr-1) when growing on glucose as the only carbon source. In this type of strains, the overexpression of several genes involved in carbon utilization occurs as a response to carbon limited conditions. Accordingly, the cell is capable of coutilizing glucose with several other carbon sources that are not only carbohydrates. The absence of functional PTS (PTS-) permits the coexistence of glycolytic and gluconeogenic pathways in this type of strains [6-8]. PTS- strains have been constructed with the goal of canalizing part of the phosphoenolpyruvate (PEP) not utilized in glucose transport to the synthesis of aromatic compounds [9-13]. However, as already mentioned, the absence of PTS causes poor growth on glucose. As such, PTS- strains are not suitable for aromatic production purposes. Therefore, additional modifications are required to increase glucose transport and phosphorylation capacities in the PTS- cell. Starting from the PTS- PB11 strain (derived from JM101) in which the ptsHIcrr operon was deleted, several fast growing mutants on glucose have been selected using a chemostat fed with glucose at progressively higher rates [9]. One of these fast growing mutants (μ = 0.42 hr-1), named PB12 PTS-Glc+, uses the GalP and Glk proteins for glucose transport and phosphorylation, respectively, as has been previously demonstrated. Moreover, not only the carbon glycolytic flux in PB12 PTS-Glc+ strain is highly increased as compared to PB11 [6], but also PB12 is capable of increasing the yield of aromatic compounds from glucose as compared to the wild type strain (Fig. (Fig.1)1
Results Coutilization of glucose and other glycolytic carbon sources by PB12 Strain PB12 presents a high glycolytic carbon flux when glucose is used as the only carbon source [6]. Therefore, the capacity of coutilizing several glycolytic metabolized carbon sources was analyzed in this strain. As shown in table 1 and figure figure2,2
Aromatic metabolite production in strain PB12 using different mixtures of carbohydrates as carbon sources With the goals of increasing the production of the first aromatic intermediate metabolite of the shikimate pathway, 3-deoxy-D-arabino-heptulosonate 7-phosphate (DAHP) and of measuring the carbon flux in this pathway by avoiding its transformation into subsequent compounds, a mutation in the aroB gene in strain PB12 was constructed (details in Methods). This mutation cancels the transformation of DAHP into 3-dehydroquinate (DHQ) (Fig. (Fig.1).1 • DAHP production in PB12 aroB-(pRW300aroGfbr pCLtktA) resting cells As can be seen in figure figure4,4
• Aromatic intermediate production in the fermentor by the strain PB12 (pRW300aroGfbr pCLtktA) Figures Figures55
Discussion The deletion of the ptsHIcrr operon exerts pleiotropic effects on the general physiology of the cell. PB11 grows very slowly (μ = 0.1 hr-1) when cultured on glucose as the only carbon source due to its inability to efficiently transport and phosphorylate glucose. Under such conditions, a nutrient scavenging stress response is induced which is responsible for the overexpression of many genes encoding carbon transport and metabolism proteins [7,8]. Due to the lack of the EIIAGlc component, mainly responsible for catabolite repression, the PB11 strain is capable of coutilizing secondary carbon sources in the presence of glucose. The induction of several cAMP/CRP regulated genes in this strain suggests that the adenylate cyclase is still producing cAMP and unpublished evidence indicates that less cAMP is produced in the PB11 and PB12 strains as compared to the paternal JM101 strain (de Anda unpublished results). Nevertheless, there is apparently enough cAMP to allow the transcription of many cAMP-CRP regulated genes in these PTS- strains [7,8]. Additionally, the transcription of the rpoS gene, that encodes the sigma factor RpoS for growth on non-optimal conditions, is upregulated in these strains. It is known that RpoS regulates various operons, including glycolytic genes, when E. coli. cells are grown in non-optimal conditions [8,17-22]. Strain PB12 PTS-Glc+, derived from strain PB11PTS- in an adaptive evolution process, is capable of growing faster on glucose (μ = 0.42 hr-1). It has been previously demonstrated that when strain PB12 carries plasmids with the tktA and aroGfbr genes, the overexpression of these genes is responsible for canalizing part of the PEP, not utilized in glucose transport due to the absence of PTS, to the synthesis of aromatic compounds [9-14]. In this report we have demonstrated that strain PB12 is still capable of coutilizing other carbohydrates with glucose. This capacity was explored with the goal of further increasing the production of aromatic compounds in minimal medium, using strain PB12(pCLtktA, pRW300aroGfbr). The obtained results indicate that certain carbohydrate mixtures, especially glucose-glycerol, increase the capacity of aromatic metabolite production in both, resting cell and fermentor experiments. Such capacity was enhanced by more than six-fold (5.00 to 31.33 mmolC/L) in the case of DAHP in the fermentor experiments when compared to glucose as the only carbon source. Interestingly, less biomass (1.4 g/L) was produced in the glucose-glycerol mixture than in the other cultures and no acetate was detected in the glycerol and glucose-glycerol cultures. Furthermore, the yield of aromatics compounds obtained in this last mixture in batch conditions (0.36 mmolC/mmolC) is high and represents 53% of the maximum theoretical yield. It is important to emphasize that the presence of these two carbohydrates as carbon sources increased the μ of PB12, as compared to the value obtained on glucose or glycerol. However, when the glucose-glycerol mixture was used by the PB12 strain carrying both plasmids – pCLtktA and pRW300aroGfbr – in the presence of IPTG where, as mentioned the best yield of aromatic compounds was obtained, then its μ was reduced as compared to the one obtained on glucose, although the lag phase was half of that obtained on glucose alone. It has been proposed that the presence of plasmids, which was confirmed during different fermentation steps, and the induction of the transcription of the aroGfbr gene with IPTG could cause a metabolic burden responsible for slower specific growth rates and longer lag phases, like the one obtained in the glucose culture [14]. The increased production of aromatic compounds is probably not only the result of a different carbon utilization capability but also of a modified carbon flux metabolism than the one present when the cell is grown only on glucose. Glycerol enters the glycolytic pathway as glycerol-3P and it is transformed to 3-dihydroxyacetone-phosphate (DHAP); this compound isomerizes to glyceraldehyde 3-phosphate (G3P) (Fig. (Fig.1).1 It is also interesting that no acetate was detected during the growth on glycerol and in the glucose-glycerol mixture in the fermentors, while acetic acid was produced in other mixtures, especially in those where the strains grew faster. This last result indicates that while PB12(pCLtktA pRW300aroGfbr) was coutilizing glycerol and glucose, it could also be utilizing previously produced acetate. Alternatively, the cells might not be producing large amounts of acetate in these conditions. This last alternative is in agreement with the low μ of this strain under the growth conditions in the fermentor. In accordance with this last proposition are the smaller qs values obtained for PB12(pCLtktA pRW300aroGfbr) strain on all the different carbon sources as compared to those obtained for strain JM101. In strain PB12(pCLtktA pRW300aroGfbr) such condition could diminish metabolic overflow which is responsible for acetate production. These results are interesting and indicate that the capacity of coutilizing certain carbohydrate mixtures is an important characteristic that allows this strain important carbon flux rearrangements. Namely in the case of the glucose-glycerol mixture, it diminishes its specific growth rate, increasing time of production, but enhancing the yields and productivities of aromatic compounds and reducing acetate production. These results indicate that strains that grow slower that the parental wild type could be better production strains because part of the carbon flux is utilized not for biomass and acetate production but for the synthesis of the desired metabolite. Further experiments, especially those conducted in enriched minimal media, usually utilized for the optimization of production processes [14-16,25], are required to demonstrate the real potential of this capacity under such growing conditions. Nevertheless, E. coli capability of coutilizing glucose with certain carbon sources in the absence of PTS is an important property that should be studied because it could have useful industrial possibilities. Certainly, the use of E. coli strains lacking the PTS system, with additional mutations and in which several other genes coding for enzymes involved in the aromatic pathway are overexpressed, have been already described for the production of aromatic molecules like shikimate, a precursor of Tamiflu, an antiviral drug that could be used in a possible influenza pandemia. Optimized processes have been reported that allow the production of around 70 g/lt of shikimate with a yield of 0.26 g shikimate/g glucose and a total aromatic yield of 0.328 g/g glucose in feed-batch fermentations using enriched minimal medium [26]. Our group has already reported the utilization of strain PB12 derivatives to overproduce phenylalanine, using enriched minimal medium at the level of 1 lt. fermentors. In these conditions, the yield of L-phenylalanine from glucose increased 65% as compared to the isogenic PTS+ strain [13,14]. Preliminary results using derivatives of strain PB12 in which the overexpresion of certain genes coding for enzymes involved in the shikimate pathway was achieved in enriched minimal medium at the level of 1 lt. fermentors, produce 7 g/lt of shikimate with a yield of 0.282 g shikimate/g glucose and a total aromatic yield of 0.39 g/g glucose (unpublished results). Additional mutations that we are incorporating in PB12 production derivative strains (like pykA and or pykF to modulate the glycolytic flux, and a mutation isolated in another PB12 derivative that allows very fast growth rates in acetate [μ = 0.9 hr-1]) could increase the production capabilities of PB12 and other PTS- derivative strains. Finally, an additional consideration about the importance of characterizing these PTS- strains is that in the scenario of a world influenza pandemia, it is important to develop national and regional capabilities to produce antiviral drugs like Tamiflu or Relenza and the next generations of antiviral aromatic molecules, using biotechnological strategies with optimized engineered strains. Methods Bacterial strains and plasmids E. coli strains and plasmids used in this study are presented in table 5.
Genetic procedures and recombinant DNA techniques PCR reactions were performed using Platinum Taq polymerase according to the manufacturer recommendations (Invitrogen, Ca., USA). The DNA sequences of the oligonucleotides (DAB1 and DAB2) for the interruption of the aroB gene are presented in table 6. This table also includes the sequences of the oligonucleotides (SAB1 and SAB2) utilized for demonstrating the interruption of the aroB gene in strains JM101 and PB12. Mutagenesis of the aroB gene in strains JM101 and PB12 was obtained using the Datsenko and Warner methodology [27]. This method utilizes a λ phage derivative and low copy number plasmid pkD45. Details of the procedure have been described elsewhere [27].
Growth conditions • Batch cultures M9 medium, consisting of (per liter): Na2HPO4, 6 g; KH2PO4, 3 g; NaCl, 0.5 g; NH4Cl, 1 g; MgSO4, 2 mM; CaCl2, 0.1 mM; Vit B1, 0.01 g, and glucose, 2 g, was utilized for growing fermentor inocula. A higher concentration of glucose or other carbohydrates (4 g/L, around 130.00 mmolC/L, depending of the molecular weight of the carbon source), was utilized in the fermentor (1 L, working volume: 0.75 L) studies when only one carbon source was employed. When two carbon sources were used, the same amount of each (2 g/L, approximately 65 mmolC/L) was employed. IPTG (0.1 mM) was added at the beginning of the fermentation. Tetracycline (30 μg/ml) and spectynomycin (100 μg/ml) were included in the medium for plasmid maintenance. • Resting cells ARO medium (per liter: K2HPO4, 14 g; KH2PO4, 16 g; NH4SO4, 5 g, and MgSO4, 1 g) with glucose (7 g/L) and 10 g/L yeast extract were utilized for growing the inocula in resting cell experiments. Inocula were washed twice with ARO medium and resuspended in 50 ml of the same medium in 250 ml shake flasks, lacking yeast extract and supplemented with aromatic aminoacids, vitamins, L-tyrosine (8 mg/L), L-tryptophan (4 mg/L), L-phenylalanine (8 mg/L), p-aminobenzoic acid (62 mg/L), dihydroxibenzoic acid (35 mg/L), and p-hydroxibenzoic acid (2 mg/L). Glucose or other carbohydrates were added at a final concentration of 7 g/L (around 228 mmolC). When a mixture of two carbohydrates was employed, equal amounts of both (3.5 g/L; approximately 114 mmolC) were utilized. For resting cell experiments, IPTG (0.1 mM) was added after one hour of fermentation. In these conditions E. coli cells do not grow but are still metabolically active and can canalize carbon skeletons into the production of aromatic compounds [12,28]. For plasmid maintenance, (30 μg/ml) and spectynomycin (100 μg/ml) were utilized. Kinetic and stoichiometric parameters • Batch cultures Data represent the average of at least three different cultures. Cell growth was measured by monitoring the optical density 600 nm (OD600) in a spectrophotometer (Beckman DU700). OD600 was converted into dry cellular weight (biomass concentration) using a standard curve (1 OD600 = 0.37 g/L of dry cellular weight). Specific growth rates (μ) were determined by fitting the biomass data versus time to exponential regressions. The biomass yield (YX/S) was estimated as the coefficient of linear regression of biomass concentration versus substrate concentration (glucose, arabinose, glycerol, gluconate, or glucose plus other carbon source) in grams of biomass/mmolC of substrate(s). The specific carbon consumption rate (qS) was determined as the ratio of μ to YX/S. Cells were grown in the fermentor on glucose alone or glucose and either arabinose, glycerol, or gluconate as carbon sources. • Resting cells Specific glucose consumption and product formation rates were determined for each strain by linear regression of four data points over the 12-hr time span of an experiment. Constant DAHP production and carbohydrate consumption rates were found for all strains indicating that carbon catabolism was in a physiological quasi-steady-state [12,28,29]. For aroGfbroverexpression, cells were grown in the presence of 0.1 mM IPTG. Analytical methods Metabolite concentrations were determined with an HPLC system (600E quaternary bomb, 717 automatic injector, 2410 refraction index, and 996 photodiode array detectors, Waters, Milford, MA). For determination of D-glucose, L-arabinose, D-glycerol, 3-dehydroshikimate (DHS), shikimate (SHIK) and acetic acid, an Aminex HPX-87H column (300 7.8 mm; 9 Am) (Bio-Rad, Hercules, CA) was used. Running conditions were: mobile phase, 5 mM H2SO4; flow, 0.5 mL/min, and temperature, 50°C. Under these conditions glucose and acetic acid were detected by refraction index. D-gluconic acid was determined by enzymatic assay (Boehringer-Mahheim, Darmstadt, Germany). DAHP concentrations were determined using the thiobarbituric assay [30]. Conclusion PTS- strains are capable of coutilizing different mixtures of carbon sources due to the lack of glucose catabolite repression. The PTS- strain PB12, carrying multicopy plasmids with tktA and aroGfbr genes, was capable of coutilizing glucose and glycerol. This capacity diminished its specific growth rate but increased six-fold the production of DAHP, and the production of acetate was not detected. These results suggest that at least in this PTS- strains in these growing conditions, slower growth rates allow better carbon utilization strategies for production purposes, diminishing metabolic overflow. Competing interests The author(s) declare that they have no competing interests. Authors' contributions KM and FB designed experiments, analyzed the results and wrote the manuscript. KM carried out the experiments while GH and RA helped with analytical and fermentation experiments. AE, GG and OTR critically revised the results and the manuscript. All the authors have read and approved the publication of the manuscript. Acknowledgements We thank M. Enzaldo, R. Martínez, B. Urióstegui, and J. Salazar for their technical assistance. We are also grateful to Paul Gaytán, Jorge Yáñez and Eugenio López for the synthesis of oligonucleotides and M. Sánchez-Alvarez for proof-reading the manuscript. This work was supported by grants 43243-Z and 44126 from Consejo Nacional de Ciencia y Tecnología and grant PAPIIT IN220403-2 from UNAM, México. References
|
PubMed related articles
Your browsing activity is empty. Activity recording is turned off. |
|||||||||||||||||||||||||||
BMC Microbiol. 2007 Jun 8; 7():53.
[BMC Microbiol. 2007]Metab Eng. 2002 Apr; 4(2):124-37.
[Metab Eng. 2002]J Mol Microbiol Biotechnol. 2005; 10(1):51-63.
[J Mol Microbiol Biotechnol. 2005]Nat Biotechnol. 1996 May; 14(5):620-3.
[Nat Biotechnol. 1996]Biotechnol Bioeng. 2004 Aug 20; 87(4):516-24.
[Biotechnol Bioeng. 2004]Metab Eng. 2002 Apr; 4(2):124-37.
[Metab Eng. 2002]Nat Biotechnol. 1996 May; 14(5):620-3.
[Nat Biotechnol. 1996]Microb Cell Fact. 2007 Aug 21; 6(1):28.
[Microb Cell Fact. 2007]Metab Eng. 2005 Mar; 7(2):70-87.
[Metab Eng. 2005]J Mol Microbiol Biotechnol. 2005; 10(1):51-63.
[J Mol Microbiol Biotechnol. 2005]Nat Biotechnol. 1996 May; 14(5):620-3.
[Nat Biotechnol. 1996]Microb Cell Fact. 2007 Aug 21; 6(1):28.
[Microb Cell Fact. 2007]Microb Cell Fact. 2007 Aug 21; 6(1):28.
[Microb Cell Fact. 2007]Microb Cell Fact. 2007 Aug 21; 6(1):28.
[Microb Cell Fact. 2007]Biotechnol Bioeng. 2004 Aug 20; 87(4):516-24.
[Biotechnol Bioeng. 2004]Microb Cell Fact. 2007 Aug 21; 6(1):28.
[Microb Cell Fact. 2007]Proc Natl Acad Sci U S A. 2000 Jun 6; 97(12):6640-5.
[Proc Natl Acad Sci U S A. 2000]Biotechnol Bioeng. 2001 Jun 20; 73(6):530-5.
[Biotechnol Bioeng. 2001]Ann N Y Acad Sci. 1994 Nov 30; 745():21-34.
[Ann N Y Acad Sci. 1994]Biotechnol Bioeng. 2001 Jun 20; 73(6):530-5.
[Biotechnol Bioeng. 2001]Ann N Y Acad Sci. 1994 Nov 30; 745():21-34.
[Ann N Y Acad Sci. 1994]J Biol Chem. 1959 Apr; 234(4):716-22.
[J Biol Chem. 1959]